Please login to the form below

Not currently logged in
Email:
Password:

PARP inhibitor

This page shows the latest PARP inhibitor news and features for those working in and with pharma, biotech and healthcare.

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

the punch in prostate cancer, a potentially lucrative new indication for the PARP class. ... A combination trial of Rubraca plus Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) – called CheckMate 9KD – is also ongoing with initial

Latest news

More from news
Approximately 9 fully matching, plus 105 partially matching documents found.

Latest Intelligence

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate).

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The PARP inhibitor drug prevents BRCA mutation-carrying cells from repairing themselves, causing them to die. ... KUDOS had discovered olaparib, the first-in- class PARP inhibitor, which Galbraith’s team developed and brought to market as Lynparza.

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute

  • Deal Watch April 2016 Deal Watch April 2016

    3, 340. Nimbus Apollo (US). Gilead (US). Company acquisition. Phase I Acetyl-CoA Carboxylase (ACC) inhibitor programme for live disease. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics